Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Summary

Considering the accumulated data on the pathogenesis of multiple sclerosis, indicating a significant role of B cells in the progression of the disease, the use of monoclonal antibodies to CD20 antigen, administered intrathecally to achieve adequate B-lymphodepletion in the barrier tissues can increase the duration of the recurrence-free course of autoimmune diseases, suspend their progression, and also prevent clinical relapse when memory B cells are detected.

Timeline

Start

2020-12-21

Primary completion

2022-12-21

Completion

2024-12-21

Drugs

Indications